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Using Platelet-Rich Plasma to Reverse the
Effects of Tendinopathy and Prevent Tendon
Re-rupture after Surgery in Athletes:
The Search for a Standardized Protocol
By Shiv Patel
Abstract
30-50% of all lesions amateur and professional sports players will experience during activity are related to the tendon. Moreover, the incidence of tendinopathy, a precursor to tendon
rupture, is much higher in both of these groups due to excessive loading of tendons during
physical activity, insufficient rest afterwards and certain antibiotic use. The tendon anatomically has both a low blood supply and a low cell turnover rate, which contribute to the relative ease
by which an athlete can develop tendinopathy. Chronic tendinopathy has very few high-success
treatments but in recent years, platelet-rich plasma (PRP), a treatment in which platelets are
isolated from the patient’s blood and injected back into the diseased tendon, has seen promising results. Prior research has focused on assessing the viability of PRP as a treatment but failed
to come up with a standard and procedure protocol for its administration. In this study, PRP
is evaluated in terms of success rate, concentration of cells other than platelets, concentration
of growth factors, life of growth factors, and size and cross section of the tendon to develop
a formulation standard, injection plan, and procedure protocol for different tendinopathies.
Furthermore, a rehabilitation program that takes into account both the treatment and natural
healing process of the tendon to shorten the time the athlete spends off the field is outlined.
Introduction
Tendinopathy, a precursor to tendon rupture, “is used to describe the clinical picture of
pain and swelling of a tendon that exhibits no inflammation” (Andia, Sanchez, and Maffulli
1420). The symptoms of tendinopathy manifest when the rate of healthy tenocyte proliferation and extracellular matrix (ECM) formation is surpassed by the rate of tissue degeneration.
Because of its prevalence among athletes and non-athletes alike, tendinopathy is widely studied
with the leading research focused on cell apoptosis, angiogenesis that has escaped cell control,
or inflammation and pain, according to Andia, Sanchez, and Maffulli (1420). Despite these
efforts, not many treatments exist for tendinopathy.
In recent years, however, a new therapy by the name of platelet-rich plasma (PRP) has
demonstrated promising results for treating tendinopathy and preventing rerupture in tendons
after surgical repair. PRP is, in simple terms, a therapy in which platelets are isolated from the
patient’s blood and injected back into the affected tendon. The platelets release growth factors,
which can quicken the healing process and promote organized growth of structural proteins
such as collagen. Prior research has focused on assessing the viability of PRP as a treatment, but
all have failed to come up with a standardized procedure protocol for its administration.
In this study, PRP is evaluated in terms of success rate, concentration of platelets, concentration of cells other than platelets, life of growth factors, and size and cross section of the
tendon to develop a formulation standard, injection plan, and procedure protocol for treating
different tendinous lesions and tendinopathy. Furthermore, a rehabilitation program that takes
into account both the treatment and natural healing process of the tendon to shorten the time
the athlete spends off the court or field is outlined.
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Especially in athletes, tendinopathy, if not properly treated, can progress into tendon rupture. Joseph et al. in “Achilles Tendon Biomechanics in Response to Acute Intense Exercise”
contend that the most common tendon ruptured is the Achilles, attributed to the extreme
direct and repeated forces and intensive flexing that it experiences during activity, experiencing
loads up to 12 times the body weight (11). Sports cannot change to utilize the Achilles less, so a
preventative treatment needs to be employed to protect athletes. According to various studies,
including those conducted by Rosengarten et al. and Amin et al., normal tendon structure can
be lost just after 2 days of intense exercise, showing that tendon rupture among athletes is a very
real risk (Figure 1).

Figure 1. Image of an ultrasound tissue characterization of the Achilles tendon showing structural changes
due to loading over a period of 4 days. Day 0: Prior to exercise; Days 2 & 4: After exercise. Green regions
show uniform, intact tendon fibers and blue regions show less uniform, broken/wavy tendon fibers (Rosengarten et al. 185).

Combined with daily practices and long seasons, transient loss of tendon structure in athletes can cross the point of no homeostatic return according to Dr. Samuel Rosengarten and his
co-authors in “Australian Football Players’ Achilles Tendons Respond to Game Loads Within
2 Days: An Ultrasound Tissue Characterization (UTC) Study” (185). Due to the nature of
sporting, this can lead to permanent damage of the tendon and a decreased sporting ability for
the athlete. Constant loading and unloading of the tendon makes it more malleable, reducing
its cross-section. As there is less area for the tendon to absorb impact and more load per square
inch, the tendon damage is more likely during physical activity. Rosengarten et al., in accordance with Dr. Christophe Charousset et al., assert that the tendon is a connective tissue that
responds to mechanical loading in the short-term, defined as 24-72 hours, and the long-term,
defined as 12 weeks-years. Rosengarten et al. also believe that that intense exercise results in
changes of catabolic and anabolic activity within the tenocytes that tend to normalize after 4
days or longer and that if enough time is not given in between games and/or practices, these
microtrauma can transform into disorganization of the collagen and ECM of the tendon (183).
In all professional sports there is a rigorous practice schedule, and in some, such as baseball and
basketball, athletes have to play back-to-back games. This does not allow the athlete enough
time to rest tendons and give them the 4 days required to normalize the structure.
The tenocyte, the cell tasked with restoring the tendon ECM, is prompted by mechanical stimuli to begin reconstruction. Furthermore, the overloading of the tendon prompts the
tenocyte to upregulate large proteoglycan expression, leading to an “increase in bound water
within the ground substance, which may lead to matrix disorganization” (Rosengarten et al.
186). Thus, the tenocyte will repair the tendon to baseline strength during normal impact and
use, but hyperloading will disrupt the structure of the tendon and make it much more difficult
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for the tenocyte to repair it. Andia, Sanchez, and Maffulli add that the tenocyte responds to
continual mechanical loading with the release of cytokines IL-1β and tumor necrosis factor-α
(TNF-α), prostaglandin E2 (PGE2), and neuropeptides P, and connective tissue growth factor
(CTGF), all of which are pro-inflammatory agents (1422). Fox et al. agree, discussing that tendinopathy is correlated with an increase in inflammatory cytokines TNF-α and IL-1β (2855).
PRP is usually prepared free with few leukocytes and other inflammatory cells and many its
growth factors. When injected into the tendon, the growth factors overtake the inflammatory
cytokines already present in the injured tendon in concentration levels and promote faster healing.
Most sports require frequent extension of one or more tendons, leading to tendinopathy
and in some cases, tendon rupture. Hyperloading of the tendon in a short bout of physical
activity causes the tendon to experience microtrauma, weakening its overall structure, Amin et
al. write in “Performance Outcomes after Repair of Complete Achilles Tendon Ruptures in National Basketball Association Players” (1868). Charousset et al. concur, finding that tendinopathy is a result of exercise-induced microruptures within the tendon. Professional athletes cannot
avoid exercise, as it is the nature of their career so a proper preventative treatment needs to be
developed. Charousset et al. also attribute tendinopathy to “microruptures of the patellar tendon, incomplete healing, and extensive neovascularity that may lead to a chronic degenerative
process” (907). Over time, microruptures can build up and ultimately cause a rupture in one
or more tendons. If PRP is administered to the tendons that the athlete loads and unloads the
most, the microruptures within those tendons can be healed faster, which allows the athlete to
play back-to-back games and conform to intense practice schedules without fear of long-term
tendon damage. PRP injections at the first signs of tendinopathy can introduce vital healing
growth factors such as PDGF, which promotes type I collagen growth, and vascular endothelial
growth factor (VEGF) and platelet derived angiogenesis factor (PDAF), which increase blood
flow to the inside of the tendon according to the review of research conducted by Andia, Sanchez and Maffulli. Collagen is important to tendon healing and described by Mark D. Rekhter
as “proteins that consist of a triple helix of polypeptide chains and globular domains,” in his
article “Collagen Synthesis in Atherosclerosis: Too Much and Not Enough” (376). The tough
buildup of collagen insures protection from mechanical stress and impact from sports-related
activities.
Tendinopathy is extremely prevalent in sports as indicated in numbers by Charousset et
al., which is why a high-success treatment such as PRP needs to be perfected. PRP treatment
may not only save the careers of athletes in sports with high incidences of tendinopathy, such
as volleyball and basketball, but also promote more competition by retaining elite athletes for a
longer period of time. In the study by Amin et al., it is shown that even with PRP treatment, an
athlete’s game time is reduced after an Achilles tendon rupture, but specific performance factors
such as rebounds, steals, and blocks normalized when the time played was used as a reference
frame against the control instead of a per-game reference frame (1865). This data shows that
although PRP may not allow an athlete to fully regain their stamina, it will enable him or her to
retain their capabilities as an athlete.
Platelet-Rich Plasma as a Treatment
According to Sánchez et al., tendon healing is a complex process that starts with the secretion of cytokines from broken alpha granules in platelets, which signal cells within the tendinous tissue to proliferate and construct the ECM (246). Despite the many growth factors that
aid tendon healing, the tendon healing process is a slow one due to its insufficient blood supply
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and low rates of cell division (Sánchez et al. 245). Blood supply to an injury site is vital as the
circulatory system is the path through which platelets, growth factors, and other reparative
molecules are delivered. The healing process of the tendon, according to Sánchez et al. “involves
several stages, including angiogenesis, cell proliferation, and the deposition of extracellular matrix. These stages are followed by remodeling and maturation, during which the healing tendon
should ultimately regain its mechanical strength” (245). Andia, Sanchez, and Maffulli disagree
slightly and propose that the three stages to the healing process of tendons after trauma are, in
order, “inflammation, angiogenesis, and proliferation” (1418). Although the healing process
of the tendon is not completely agreed upon, the important fact is that the tendon requires a
continuous blood supply, growth factors to signal proliferation, and growth factors to signal the
secretion of a well-structured ECM to heal itself.
The plethora of growth factors and cytokines secreted by platelets help spur cell growth
and promote quick repair of the damaged region. Platelets are produced by bone marrow cells
called megakaryocytes, that make up approximately 1.4 – 4 x 1011 cells/liter of the blood, and
circulate for approximately 10 days according to Abrams and Dugdale. Platelets are short-lived,
so once PRP is prepared, it needs to be injected immediately. Andia, Sanchez, and Maffulli further discuss that growth factors such as TGF-β, PRGF-BB, and angiopoietin-1 secreted by the
platelets aid in stabilizing blood vessels, which move along the healing process (1417). Stabilizing blood vessels is of paramount importance, as unstable blood vessels can do more harm than
good and cause uncontrolled growth of inflammatory tissue.
The mechanism through which PRP works is simple: it provides an abundance of platelets that can secrete growth factors through alpha granules to synthesize collagen and promote
organized angiogenesis (Charousset et al. 909, Sánchez et al. 246). PRP exploits the natural
healing ability of platelets, providing a safe auto-derived treatment with minimal side effects.
Hom-Lay Wang and Gustavo Avila simply describe PRP as “essentially an increased concentration of autologous platelets suspended in a small amount of plasma after centrifugation” (192).
Centrifuging whole bloods draws platelets out of the blood and separates it from other components. PRP also includes structural proteins including fibrin, fibronectin, and vitronectin that
help rebuild the tendon by “facilitat[ing] cell adhesion by forming three-dimensional scaffolds”
(Andia, Sanchez, and Maffulli 1418). The fibrin matrix aids in building the scaffolding complex, a precursor to tenocyte proliferation (Sanchez et al. 246). If the fibrin matrix is synthesized
outside of the cell, and injected, there would be a higher concentration of growth factors that
are able to contribute to the healing process. Also, the fibrin matrix seems to be stimulating the
growth of collagen I, the most uniform and structurally sound form of collagen, which means a
faster and better overall recovery.
PRP is a viable treatment option for tendinopathy and tendon rupture (Figure 2), as it
introduces platelets to the tendon, which stimulate the production of collagen type I. Sánchez
et al. also concur adding that PRP contains “TGF-β1, PRGF [PRP], VEGF, epithelial growth
factor (EGF), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF-I)” (246).
These molecules produce vital signals that stimulate the synthesis of structural proteins. Furthermore, Andia, Sanchez, and Maffulli reason that the expression of genes IGF-I and TGF- β1
are important to the healing process of tendons and control the type of collagen being synthesized and that platelets modulate inflammation by controlling a plethora of chemokines that, in
turn, control the movement of leukocytes and monocytes at the injury site (1418). This creates
a positive feedback loop in which growth factors flood the cells, drive out inflammatory cytokines (which upregulates growth factors), and so on.
Healthy vascularization is important in tendons so that growth factors can be circulated
to the damaged area. Sánchez et al. report that the production of VEGF and HGF in tenocytes
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helps vascularize the tendon (246). This gives the injured tendon the blood supply that it needs
to heal quickly.

Figure 2. A) MRI of partial patellar tendon rupture before PRP treatment B) MRI of patellar
tendon 3 months after 3 PRP injections (Charousset et al. 907)

Role of Fluoroquinolones in Tendon Rupture
Fox et al. in “Fluoroquinolones Impair Tendon Healing in a Rat Rotator Cuff Repair Model: A Preliminary Study” assert that there has been a recent trend in fluoroquinolone (FQ)-related tendon ruptures. The rate of incidence of FQ-induced tendon rupture is low 0.14-0.4% (it
is much higher in transplant patients at 12.2-15.6%), Fox et al. claim, but has far-reaching consequences due to FQ’s status as the most prescribed family of antibiotics in the United States
in 2011 according to Mercola.com (Fox et al. 2852). The side effects of FQ antibiotics may
be especially stark for the transplant patients because they are already in a weakened state and
there are few growth factors present in the tendons. Increasing the amount of growth factors in
circulation may lower the chances for tendon rupture in transplant patients even without PRP
treatment.
Due to their effectiveness in eliminating both gram-positive and gram-negative bacteria,
FQs are the best treatment currently for treating tough bacterial infections. Simonin et al. argue that FQs are not dangerous most of the time to most of the population, generally speaking (869). However, if a professional athlete acquires an infection that requires the use of FQ
antibiotics, they may experience tendon rupture due to extensive use. Constant loading of the
tendon after FQ has already mutated tenocytes within it may cause the tendon to overstress and
rupture. Thus, it is important to administer PRP to high-impact tendons such as the Achilles
in athletes to help reverse the side effects of FQs and serve as a layer of protection while they are
taking the antibiotics.
It is not fully known how FQs affect the body, but Simonin et al. suggest FQ antibiotics’
high tissue penetration to be a possible reason for inducing tendon rupture (867). This allows
the antibiotics to cause mutations in tenocytes for a longer period of time. Structural proteins
are important, as their name implies, in maintaining tendon conformity, but FQs reduce their
expression in the extracellular matrix, including those of “type I collagen, elastin, fibronectin,
and b1 integrin” and also “reduced mitochondrial activity, [caused] direct toxicity on collagen,
elevated levels of activated caspase 3 (an apoptosis marker), and non-cytotoxic inhibition of
canine tendon cell proliferation” (Fox et al. 2858). Combined with their high tissue penetration
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and their ability to induce apoptosis, FQs can wreak havoc inside the tendon and disrupt tendon structure.
In addition to repressing and activating certain genes, FQs cause an influx in reactive oxygen species (ROS) in cells, resulting in a decrease of type I collagen synthesis, according to
Baboldashti et al. (1935). Baboldashti et al. further explain that the ROS decrease collagen
synthesis because they activate the transcription factor FOXO1, which is a repressor for type I
collagen synthesis (1935). Type I collagen is important in maintaining tendon structure and if
the FQ is targeting it, this can be the cause of tendon rupture in patients treated with FQ. The
oxidative changes induced by pefloxacin manifested a few days after treatment, supporting the
findings of other studies. FQ seems to be deeply penetrating tissues and affecting them slowly.
For example, Simonin et al. add that the ROS modulation of collagen synthesis was seen at least
5 days after FQ administration (871). In the study conducted by Fox et al., the tendons of the
test subjects treated with FQs failed structurally.
Fox et al. discovered that the FQs inflicted microtrauma upon the healing enthesis, weakening the entire tendon (2858). This demonstrates that FQ exposure directly affects the weakening of tendon structure. Less fiber at the healing enthesis not only means compromised structural integrity but also a lowered ability to heal in the long term.
Similarly, structurally weak collagen synthesis lowers the ability of the tendon to securely
bind to the bone (Joseph et al. 1181). With less calcified fibrocartilage to shield the bone, the
tendon has a higher chance of rupturing. For this reason, the body goes into a “fibroproliferative response, presumably in an attempt to repair the tendon defect resulting from the depletion
phase” (Simonin et al. 870). The presence of a natural repair mechanism indicates that the body
is trying to reverse the adverse effects of the FQ but is not necessarily effective in doing so. As
shown in the study by Rosengarten et al. and Fox et al., the body may be promoting the growth
of collagen types that reduce the structural integrity of the tendon. Also, the tendon fibers may
not be growing uniformly, resulting in disorganization and again, a compromised structure.
PRP injections can be given at the healing enthesis and spread from there to mitigate the chance
of rupture. It also means that tendon integrity at the organizational level has been damaged in
some way to yield these results.
FQs are known to promote the growth of collagens types II and III, according to Rosengarten et al., instead of the ones useful to tendon structure (collagen type I), causing a lapse in
integrity (185). FQ-related tendinopathy has been correlated with a downregulation of tissue
inhibitor of metalloproteinase (TIMP-2), an effect known to be associated with tendinopathy, and disorganization of collagen and fibrocartilage (Fox et al. 2855). TIMP is an especially
important regulatory factor and, if not balanced correctly, can cause tendinopathy and other
disorders of the tendon. TIMP expression, and thus collagen type II and III synthesis, can be
reduced with the introduction of inhibitory molecules and flooding the system with collagen
type I growth factor PDGF (Wang and Avila 192).
Finally, FQs are linked to gene expression in some way because of their effect on the production and inhibition of proteins and molecules. FQs upregulate factors that mark cells for
apoptosis and prevent expression of those that are important to cellular structure. The ECM is
extremely important to tendon structure and FQs are altering the concentration of apoptosis
markers and other chemicals within the matrix. This imbalance is most likely the reason for
tendon disorganization.
Application of Platelet-Rich Plasma in Sports
Andia, Sanchez, and Maffulli draw attention to the prevalence of tendon injuries, stating
that “an estimated 30-50% of all sports lesions are painful tendon injuries that affect profesA U C T U S // VCU’s Journal of Undergraduate Research and Creativity // STEM // October 2016
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sional and recreational athletes in various anatomical locations” (1415). Christophe Charousset
et al. break this statistic down, claiming that 40% of volleyball and 35% of basketball players
are affected by tendinopathy (906). Rutland et al. concur, contending that, “overuse tendon
injuries account for 7% of the injuries seen in United States physician offices and 40% of knee
injuries in volleyball players” (166). The extremely high number of tendinopathy cases also
shows a need for an effective preventative treatment to prevent tendon rupture. The rates of tendinopathy and tendon rupture are high, in part, because of the body’s inability to heal tendons
effectively and because of the few treatment options available. Sánchez et al. in “Comparison of
Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices,” further argue
that if tendinopathy progresses into tendon rupture, it would be especially devastating because
the recovery time after operation is lengthy (246). These types of disorders can even drive athletes to abandon their careers and lead painful lives long after their sports careers are over.
Platelet-rich plasma is widely accepted as a treatment and is approved for use in sports.
The World Anti-Doping Agency states on their website, “despite the presence of some growth
factors, platelet-derived preparations were removed from the List as current studies on PRP do
not demonstrate any potential for performance enhancement beyond a potential therapeutic
effect.” Team physicians are afraid to approve this type of treatment for players, but science and
those who have used PRP stand by it. It is so effective that the World Anti-Doping Agency had
to make it clear that it is not an enhancement. Mikel Sánchez et al. in “Comparison of Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices,” imply an agreement
with the Agency’s ruling, claiming that PRP is the “safe strategy to accelerate tendon cell proliferation, stimulate the synthesis of type I collagen, and promote neovascularization both in
vivo and in vitro” (246). PRP is an extremely effective treatment and reduces the time needed
for an athlete to regain range of motion and to return to sporting (Sánchez et al. 250). Amin et
al. agree and claim that although “professional athletes have essentially limitless means at their
disposal to ensure an optimal recovery after an injury… only 60% to 70% can return to their
sport, usually at a measurably lower level of performance” (1868). PRP is a relatively expensive
treatment at its current stage, but professional sports teams have a plethora of financial resources to support the players. Furthermore, the cost of losing a player outweighs the cost of the PRP
treatment.
Research both in vivo and in vitro has demonstrated the effectiveness of PRP, even if the
results are not miraculous or a “cure-all” treatment. Especially for an injury such as an Achilles
tendon rupture, coaches and team physicians should recommend PRP injections concurrent
with and after surgery, as steroid injections and other treatments have not been very successful
in the past.
Andia, Sanchez, and Maffulli claim that studies have indicated that PRP increases the
blood supply and the amount of circulation-derived cells to the injured tendon (1418). Moreover, Baksh et al. assert in “Platelet-Rich Plasma in Tendon Models: A Systematic Review of
Basic Science Literature” that most studies indicate higher vascularization of the injured tendon
and increased tendon strength after PRP treatment. PRP has only shown positive results, minimal (if any) side effects, and no deterioration from the initial state. Even if the PRP treatment
“fails,” the player can take comfort in the fact that they will not experience any rejection of or
negative reaction to the treatment, as it is derived from their own body.
Charousset et al. claim that 75% of athletes who did not respond to non-operative
treatments for tendinopathy for at least 4 months in their study were able to return to their
pre-symptom sporting level after PRP treatment (909). This comes in contrast with operative
measures, which only allow 50-70% of treated athletes to return to their pre-symptom sporting
levels (Charousset et al. 909). These are almost indisputable numbers, and team physicians have
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a responsibility to inform players about PRP therapy because they have a right to know what
their options are.
In “Performance Outcomes after Repair of Complete Achilles Tendon Ruptures in National Basketball Association Players,” Nirav Amin et al. found that after Achilles tendon ruptures, not only did the NBA players have reduced performance in those activities that heavily
relied on the tendon such as rebounds, steals and blocks, but they also had reduced abilities in
every other component of the game (1869). Amin et al. also found that 36% of NFL players
who had surgically repaired Achilles tendons and 39% of NBA players (sample size: 18) were
unable to return to the game (1868). Parekh et al. in “Epidemiology and Outcomes of Achilles
Tendon Ruptures in the National Football League” similarly found that 36% of NFL players
who experienced Achilles tendon ruptures did not return to the game and add that those who
did had over a 50% reduction in performance (285). If PRP is concurrently administered with
surgical repair of the tendon, and this practice is standardized, then these numbers would be
much lower. This assertion is corroborated in the study conducted by Sánchez et al., who reported that “two of the amateur athletes in the [PRP] group (soccer and basketball) attained
preinjury level by 6 months, whereas the 2 remaining athletes (soccer) retired from competitive
sports for reasons other than the injury; however, their level of activity was high” (249).
Surgical repair of Achilles tendon ruptures is usually the best option for professional athletes so that they can return to the game, but it is not enough for athletes to stay in the game.
Andia, Sanchez, and Maffulli report that PRP treatment is also not without risk, as it can decrease the cross-sectional area of a tendon after 18 months (1419).
Dr. Nasim Baboldashti, a researcher at the University of Oxford, and his colleagues
suggest that PRP can also be used as a “protective strategy at the time of local drug injection to
prevent some of the adverse side effects of steroids and fluoroquinolones” (1931). Steroids have
been shown not to be effective treatments against tendinopathy like in the experiment conducted by Baum et al., but PRP looks hopeful as a preventative treatment for tendon rupture when
administering fluoroquinolones.
Recommendations on the Use
of PRP
There are approximately
1.4 – 4.0 x 1011 platelets/liter
of blood, and each platelet has
a lifespan of ~10 days (Woodell-May et al. 749). According to
the review conducted by Baksh
et al., formulations of PRP were
dependent on the individual
and varied from 2 – 7 times the
normal platelet concentration.
Figure 3. Chart detailing suggested concentrations of platelets in PRP In this study, these concentraformulations for recommended protocol in different tendons/tendinop- tions and their effectiveness were
athy.
taken into account and matched
with types of tendinopathy/tendon rupture (used concurrently with surgery; Figure 3).
PRP is not only effective because of the molecules it contains but also because of those
it does not. Charousset et al. assert that in many studies such as McCarrel and Fortier’s, it
was “demonstrated that leukocyte concentration is positively correlated with catabolic gene
A U C T U S // VCU’s Journal of Undergraduate Research and Creativity // STEM // October 2016
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expression in tendons and ligaments, which suggested that delivery of concentrated leukocytes
to a site of injury might not provide a favorable environment for tissue healing” (909). Introducing leukocytes to the tendon during its healing process is not favorable, as the leukocytes
are attacking the tendon tissues in the absence of pathogens and causing sterile inflammation.
Creating an environment with minimal leukocytes may promote better and faster healing, as it
prevents the onset of sterile inflammation. However, it may put the patient at risk for infection
if they have an already weakened immune system. For this reason, few white blood cells should
be included in the formulation. Fontenot et al. agree with this assertion to an extent, claiming
that white blood cells aid in tissue repair by warding off microbes and maintaining an immune
system presence in the injured area (1270).
Commercial preparation of PRP is very efficient and the best option in the long-term.
Although the upfront cost is significantly greater than other methods, the efficiency, reduction in chance for human error, and simple processing of whole blood make it suitable for a
clinical setting. Charousset et al. used the Arthrex ACP system to isolate platelet-rich plasma
from whole blood. The ACP contained more than two times the density of platelets than whole
blood (907). The preparation process is simple according to Charousset et al. who drew 15 mL
of venous blood “into the Arthrex Double Syringe System (Arthrex Inc.) and then centrifuged
at 1700 rpm for 5 minutes. A final volume of 6 mL of pure PRP was obtained” (907).
The most effective concentration of platelets in the PRP in relation to whole blood is
debated and varies from 2-10 times. However, as Fontenot et al. point out, “some studies suggest that high platelet numbers are no better than moderate numbers or may actually have
detrimental effects” (1267). It is better to be on the safe side and inject a lower concentration
of platelets and then administer more injections than to do the opposite. After reviewing the
literature and comparing different tendon densities, tensile strengths, and size, a guide to concentration levels was developed (Figure 3).
PRP can be harmful or useless without the correct formulation, so balancing how much
PRP injected is of paramount importance. The current protocol devised by Dr. Peter Wehling, according to the Chicago Tribune, is to extract PRP serum from ~60mL of blood to and
inject it into the patient’s tendons six times over the treatment course. This treatment can be
used as a guide but needs to be tailored according to tendon density and size to be most effective. A blanket treatment may even do more harm than good if too much tissue is regenerated
according to the mechanism described by Wang and Avila in “Platelet Rich Plasma: Myth or
Reality?” Andia, Sanchez, and Maffulli suggest that injecting patients weekly with PRP over 2-3
weeks using ultrasonography as a guidance tool is an effective way to administer the treatment
(1420). Charousset et al. agree with this procedure protocol, adding that a 16-MHz probe gave
a clear image of the internals and that a 22-gauge needle was used to inject the PRP “within
and around the hypoechoic area” (907). Ultrasound imaging is optional but is recommended
as it allows the physician to accurately guide the injection. This allows for a more effective treatment and fewer injections over the course of the treatment. Charousset et al. add “75% [of the
treated patients] were able to return to their presymptom sporting level … after a mean period
of 3 months, and this sporting level was maintained until the 2-year follow-up” (909). The
3-month MRI in 57% of patients confirmed a complete repair of the tendon. This conservative
procedure is an alternative treatment to surgery, which has allowed only 50% to 70% of the
treated patients (either arthroscopic or open surgery) to return to a presymptom sporting level”
(Charousset et al. 909).
Even though the Arthrex Inc. preparation system mentioned previously yields high-grade
PRP, the delivery method needs to be refined. PRP needs to be injected in and around the tendon uniformly, presenting a challenge as one cannot just move up the tendon, injecting PRP at
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regular intervals on the skin. A possible solution is using the same technique used for lubricating joints with Orthovisc (high molecular weight hyaluronan) fluid—moving the needle while
it is inside the patient. This may cause the hypodermic needle to stretch the entrance hole, but
this is better than creating multiple injection sites.
PRP alone cannot miraculously cure tendinopathy and fix tendon rupture, but instead, it
has to be combined with a variety of other treatments to be most effective. One of these is physical therapy (PT). Stanish, Rubinovich, and Curwin suggest that the PT program consists of
stretching, progressive loading, and increase in the speed of exercise (66). The stretching helps
with stratifying the tendon and pain from joint movement. The load on the tendon should be
increased weekly and lessened if the patient experiences pain. Speeding up the contractions
allows the tendon to take on more force according to Stanish, Rubinovich, and Curwin (66).
The exercise program should last for at least 4 weeks but 6 weeks is recommended to ensure
complete healing and to minimize the risk of rerupture. Charousset et al. suggest that running
should be taken up after 6 weeks and sporting after 8 weeks (908).
Many studies lay claim to the ineffectiveness and potential harmful effects of PRP, yet they
fail to provide concrete data to corroborate these assertions. Studies have also erred on the side
of caution, arguing that more research is needed before PRP can be administered to patients,
as it may present extremely negative side effects in the long term. Although these claims might
be well warranted under normal circumstances in testing of synthetic drugs, PRP is derived
from the patients’ bodies and unused portions of it is metabolized soon after it is administered.
For this reason, any side effects will manifest in the short term, and no significant ones have
been documented. Of course, administering too much of any substance that interferes with
cell signaling can be harmful in large quantities, which is why in this study, the formulation
standard lies more on the conservative side. Athletes should not be over-vigilant when it comes
to making the decision of whether to try PRP or not. If alternate treatments continue to fail,
they should consider PRP as a serious option, as it has displayed extremely positive results in the
past. In the case that the treatment is successful, athletes will not only enjoy the benefit of a fast
and more complete recovery from tendon rupture and tendinopathy but will also be providing
more data on which scientists can rely and perfect PRP technology for widespread use.
PRP is a promising treatment for alleviating tendinopathy and preventing tendon re-rupture postoperatively. Although the treatment has been developed extensively in the past few
years, a standard for its administration has not been set. Gathering recommendations from
previous studies and taking into account the different tendons of the body, a comprehensive
protocol was developed in this study (Table 1). Figure 3 and Table 1 should serve as a guide
for administering PRP to athletes after tendinopathy or rupture in the tendons outlined. Ultimately, however, the provider must make the final decision on the formulation, the injection
volume, and the exercise program until there is more research on the administration of PRP.
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Table 1. Procedure for Administering Platelet-Rich Plasma
1

Establish a baseline platelet count

2

Draw 15 mL of whole blood

3

Centrifuge at speed recommended by the Arthrex ACP Double Syringe System for 5
minutes

4

Isolate platelets and check concentration, matching it to Figure 3; do not exceed an
injection volume of 2.5 mL

5

Inject PRP in and around the tendinous lesion (optional: use ultrasonography to guide
the injection)

6

Repeat procedure once a week after the first injection for 2 more weeks, for a total of 3
injections

7

Enroll patient in a therapy program focused on stretching, light extensions of the tendon, and mild exercise; increase difficulty on a weekly basis
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